XFOR Live signals | Maximize Profits with Getagraph.com

SELL 103964 min ago

@ $0.930

Issued: 14 Feb 2024 @ 09:30

Return: 26.87%

Previous signal: Feb 13 - 13:27

Previous signal: Buy

Return: -2.14 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:15):

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases...

Stats
Today's Volume	10.20M
Average Volume	2.50M
Market Cap	198.15M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.160 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.07
ATR14	$0.0110 (0.94%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	Taveras Arthur	Sell	14 235	Common Stock
2024-03-11	Ragan Paula	Sell	49 678	Common Stock
2024-03-11	Mostafa Adam S.	Sell	52 500	Common Stock
2024-03-11	Dibiase Mary	Sell	15 409	Common Stock
2024-02-13	Arbet-engels Christophe	Buy	180 816	Stock Appreciation Right

INSIDER POWER
80.28
Last 96 transactions
Buy: 15 169 198 \| Sell: 1 336 024

Volume Correlation

Long: 0.29 (neutral)

Short: -0.65 (moderate negative)

Signal:(43.63) Neutral

X4 Pharmaceuticals Inc Correlation

10 Most Positive Correlations
AVO	0.951
ALZN	0.945
FATE	0.943
TCRT	0.942
QTEK	0.937
IMCC	0.932
BVXV	0.928
FNCH	0.923
TTCF	0.921
ARQQ	0.919

10 Most Negative Correlations
DVCR	-0.955
BNIXU	-0.951
OPNT	-0.944
NTUS	-0.94
LMNX	-0.939
EWEB	-0.937
ISIG	-0.932
AVEO	-0.93
EDUT	-0.924
ITMR	-0.921

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

X4 Pharmaceuticals Inc Correlation - Currency/Commodity

0.32
( neutral )

0.55
( weak )

0.00
( neutral )

0.54
( weak )

0.00
( neutral )

-0.16
( neutral )

X4 Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.00M (0.00 %)
EPS:	$-0.570

FY	2023
Revenue:	$0
Gross Profit:	$-2.00M (0.00 %)
EPS:	$-0.570

FY	2022
Revenue:	$0
Gross Profit:	$-1.99M (0.00 %)
EPS:	$-1.480

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.99

Financial Reports:

No articles found.

X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.